New drug battle to protect Muscle-Weakness patients during risky tumor surgery
NCT ID NCT07231523
Summary
This study aims to find out which of two existing treatments works better and is safer for people with myasthenia gravis who need surgery to remove a thymoma tumor. It will compare a newer drug called efgartigimod against the standard treatment, intravenous immunoglobulin (IVIG), given around the time of surgery. The goal is to help patients have fewer muscle weakness symptoms and complications before and after their operation.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EFGARTIGIMOD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Zhongshan Hospital
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.